This study provides robust evidence supporting the use of SGLT2 inhibitors in heart failure with preserved ejection fraction. Long-term outcomes data would further strengthen these findings. - https://sentibene.ch/vertriebspartner.html , This review addresses the growing problem of metabolic dysfunction-associated steatotic liver disease (MASLD). .